{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:41:59Z","timestamp":1767836519502,"version":"3.49.0"},"reference-count":7,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2022,1]]},"abstract":"To the Editor<\/jats:title>Nearly two years after the onset of the coronavirus disease 2019 (COVID-19) pandemic,\n healthcare workers face new and unexpected complications. Although accelerating the\n vaccination process in recent months has reduced the incidence and mortality of the\n COVID-19 infection, the general population (particularly vulnerable groups) remains\n at risk of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\n variants. Over the last two months, Iran has encountered the fifth wave of the\n COVID-19 pandemic, i.\u2009e., the B.1.617.2 (Delta) variant of the SARS-CoV-2,\n with faster infectiousness and higher severity and mortality among hospitalized\n patients 1. Although fever, cough, and\n expectoration are the most common clinical features of COVID-19, recent studies have\n indicated an increasing number of skin manifestation reports in the disease.\n Besides, there is growing evidence that underlying SARS-CoV-2 infection may increase\n the risk of adverse drug reactions 2.\n However, the enduring concern in our medical centers in recent days is a raised\n incidence of Stevens-Johnson syndrome (SJS) in recovered COVID-19 patients following\n monotherapy with older antiepileptic drugs (0.004 vs. 0.0008% \u2013\n i.\u2009e., 5 times higher than the pre-COVID-19 period) 3. It is worth noting that these patients did\n not have any history of SJS\/toxic epidermal necrolysis (TEN) or additional\n etiopathogenic factors, including infections, genetic factors (particularly\n HLA-B*1502 allele), and malignancy. Furthermore, for many years before\n developing the COVID-19 and recovering from it, they had been treated with the above\n drugs without showing any cutaneous hypersensitivity reactions. These observational\n findings raise two important questions: (i) Could a history of the COVID-19\n infection be a potential risk factor for type IV hypersensitivity reactions to older\n antiepileptic drugs? (ii) If so, what are its mechanisms of action?<\/jats:p>","DOI":"10.1055\/a-1678-7429","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T23:50:27Z","timestamp":1636588227000},"page":"58-59","source":"Crossref","is-referenced-by-count":1,"title":["A Possible Type IV Hypersensitivity Reaction to Older Antiepileptic Drugs During and\n After Recovery from COVID-19 Infection"],"prefix":"10.1055","volume":"55","author":[{"given":"Mohsen","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.24171\/j.phrp.2021.0217","article-title":"How to deal with the Delta variant this fall","volume":"12","author":"J K Lee","year":"2021","journal-title":"Osong Public Health Res Perspect"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/biology9120449","article-title":"Cutaneous manifestations in confirmed COVID-19 patients: A systematic review","volume":"9","author":"C Conforti","year":"2020","journal-title":"Biology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/1744666X.2020.1740591","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: Risk factors, causality\n assessment and potential prevention strategies","volume":"16","author":"C C Lin","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"644871","DOI":"10.3389\/fmed.2021.644871","article-title":"Associations between Stevens\u2013Johnson syndrome and infection: Overview of\n pharmacoepidemiological studies","volume":"8","author":"T Imatoh","year":"2021","journal-title":"Front Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor\n Fedratinib","volume":"53","author":"D Wu","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/wound.2019.0977","article-title":"Toxic epidermal necrolysis and Steven\u2013Johnson syndrome: A comprehensive\n review","volume":"9","author":"O A Charlton","year":"2020","journal-title":"Adv Wound Care"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"omaa042","DOI":"10.1093\/omcr\/omaa042","article-title":"Hydroxychloroquine-induced Stevens\u2013Johnson syndrome in COVID-19: a rare case\n report","volume":"2020","author":"L Davoodi","year":"2020","journal-title":"Oxf Med Case Reports"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1678-7429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T16:47:38Z","timestamp":1719679658000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1678-7429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":7,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2022,1,25]]},"published-print":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1678-7429","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]}}}